Loading clinical trials...
Loading clinical trials...
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Collaborators
NCT07221500 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
NCT01306084 · Anogenital Herpes, COVID-19, and more
NCT04551378 · COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, and more
NCT05218083 · COVID-19, Critical Illness, and more
NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more
UOC Ematologia AO Cosenza
Cosenza
Ematologia AOU S.Anna
Ferrara
Ematologia AOU Careggi
Florence
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions